Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
itacitinib + osimertinib
- Development stage
- Phase 2
- Lead developer
- Incyte
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
The combination of **itacitinib** and **osimertinib** is an investigational regimen being studied primarily for the treatment of advanced or metastatic non-small cell lung cancer (NSCLC), particularly in patients with EGFR mutations that have progressed following EGFR tyrosine kinase inhibitor therapy. Itacitinib is an oral selective Janus kinase 1 (JAK1) inhibitor that modulates immune signaling and may help overcome immune-related mechanisms of cancer resistance. Osimertinib is a third-generation, irreversible inhibitor of the epidermal growth factor receptor (EGFR) tyrosine kinase that selectively targets both EGFR-sensitizing and EGFR T790M resistance mutations. This combination is under evaluation for its safety, tolerability, and antitumor activity in multiple phase 1/2 clinical trials for NSCLC.
- Other names
- itacitinib and osimertinibitacitinib plus osimertinib
02
Targets
Beyond the preview
Go deeper on itacitinib + osimertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on itacitinib + osimertinib.